Kölle E U
Fortschr Med. 1981 Jun 11;99(22):874-9.
The biotransformation pathways following oral administration of prazepam are characterized. The time course of the active metabolite descyclopropylmethylprazepam (= norprazepam), representing 80-90% of all prazepam metabolites in plasma, can be described by an open one compartment model with a mean elimination half life of 70 h and a plasma clearance of 1.0-1.4 l/h. 3-5 h after single doses of 20 mg prazepam, the corresponding peak levels of norprazepam are 120-160 ng/ml. There is only a slight uptake of norprazepam into red blood cells and a relative low secretion into breast milk. Following repeated doses of daily 20 mg prazepam steady state levels of norprazepam are 600-800 ng/ml. The slow build-up of the active metabolite and the long elimination half life ensure continuous plasma levels with small fluctuations.
描述了口服普拉西泮后的生物转化途径。活性代谢物去环丙甲基普拉西泮(=去甲普拉西泮)在血浆中占所有普拉西泮代谢物的80-90%,其时间过程可用开放一室模型描述,平均消除半衰期为70小时,血浆清除率为1.0-1.4升/小时。单次服用20毫克普拉西泮后3-5小时,去甲普拉西泮的相应峰值水平为120-160纳克/毫升。去甲普拉西泮在红细胞中的摄取很少,向母乳中的分泌相对较低。每日重复服用20毫克普拉西泮后,去甲普拉西泮的稳态水平为600-800纳克/毫升。活性代谢物的缓慢积累和较长的消除半衰期确保了血浆水平持续且波动较小。